ACCESS Newswire
12 May 2022, 23:43 GMT+10
MILAN, ITALY / ACCESSWIRE / May 12, 2022 / Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today a €3.5 million seed investment in NanoPhoria, a pre-clinical stage biotech company that is developing a versatile, non-viral drug delivery platform based on inorganic nanoparticles.
The investment was made through the Sofinnova Telethon Fund, the venture capital firm's early-stage strategy focused mainly on investments in rare and genetic diseases, and the largest fund entirely dedicated to biotechnology in Italy.
The lead product coming out of the platform is a treatment for heart failure with reduced ejection fraction (HFrEF), a chronic syndrome affecting the lives of millions worldwide.
Nanophoria was co-founded by Dr. Daniele Catalucci, Research Director at the Institute of Genetic and Biomedical Research (IRGB), National Research Council (CNR); Dr. Michele Iafisco, Senior Researcher at the Institute of Science and Technology for Ceramics (ISTEC), National Research Council; Dr. Alessio Alogna, Cardiologist and Clinical Scientist at Charité Universitätsmedizin Berlin; and the CEO, Claudio De Luca, a life science executive with more than 25 years of experience in leadership positions in medtech and biotech
'NanoPhoria is developing a cutting-edge approach for a non-viral delivery of biologics, targeted to the heart, and can count on a team of four co-founders whose skills are complimentary, with scientific, medical and industrial experience,' said Lucia Faccio, a Partner with the Sofinnova Telethon Fund. 'They are all actively involved in the management of the company.'
The company, whose versatile platform allows selective targeting at the organ and/or cellular level, has been officially recognized as a spin-off of CNR, the largest multidisciplinary public research institution in Italy.
NanoPhoria will be presenting at the upcoming BioEquity conference, Europe's premier meeting of investors and biopharma executives, which will take place in Milan from May 16-18.
'We are pleased to have the support of Sofinnova Telethon Fund as we work to consolidate our nano-delivery platform and advance our first product towards the clinic,' said Claudio De Luca, CEO and co-founder of NanoPhoria. 'Our collaboration has already proved very positive. It will
strongly contribute to the acceleration of our development programs and help us bring effective therapies to patients and address unmet clinical needs.'
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply-established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: www.sofinnovapartners.com
About NanoPhoria
NanoPhoria is a biotech company based in Milan that is developing a versatile, non-viral drug delivery platform based on inorganic nanoparticles. The company's first product is a pre-clinical stage treatment for heart failure with reduced ejection fraction (HFrEF), a chronic syndrome affecting the lives of millions worldwide. The company, whose four founders have active roles and complimentary backgrounds, is a spin-off from CNR, the largest public research institution in Italy.
Media Contacts
NanoPhoria
Daniele Catalucci, Chief Scientific Officer
[email protected]
Havas PR Milan
Pierluigi Cavarai
[email protected]
+39 (0) 392 7799933
SOURCE: Sofinnova Partners
Get a daily dose of London Mercury news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to London Mercury.
More InformationOne halcyon spring day in 1903, the 69-year-old anatomist and naturalist Dr. James Bell Pettigrew sat at the top of a sloping street...
NEW DELHI, India: Jaguar Land Rover (JLR) has decided against manufacturing electric vehicles at Tata Motors' upcoming $1 billion factory...
LONDON, U.K.: Virgin Group is seeking to raise $900 million to fund its plan to launch cross-channel rail services, positioning itself...
SEATTLE, Washington: Boeing saw a significant increase in aircraft deliveries in February, reporting 44 planes delivered compared to...
DALLAS, Texas: Southwest Airlines will start charging passengers for checked bags, ending a long-standing policy that set it apart...
NEW YORK, New York - U.S. stocks rallied hard on Friday, boosted by strong rises around the world. Investors shrugged off a decline...
MILAN, Italy: Maserati has scrapped plans for an electric version of its MC20 sports car, citing low expected demand for the high-performance...